第二届广州核酸国际论坛第三轮通知

        第二届广州核酸国际论坛(CNAF)以核酸转化研究与治疗为主题,旨在推动核酸研究和治疗药物的发展,加强中国与国际的交流合作,促进中国核酸生物产业的进步,展望核酸技术作为创新药物第三大发展引擎的美好前景。

        本届论坛特邀20多位国际顶级科学家和企业家参会演讲,嘉宾囊括诺贝尔奖得主、世界百强药企的高级主管、世界顶级学府的著名教授、核酸制药上市公司的总裁、核酸治疗世界联盟主席等,内容涵盖RNAi、microRNA、antisense、lncRNA、mRNA、exon-skipping、CRISPR等核酸技术最新进展,包括从核酸基础研究到产业化,从临床前开发到临床研究,并分享去年世界首个核酸药物成功上市的经验。论坛的召开,将为国内科学家及研究生提供与本领域学术权威面对面交流的难得机会,为国内从事生物制药的企业单位提供与世界知名药企建立合作的纽带。

        我们期待与您相聚美丽羊城,共同迎接核酸治疗时代的来临!

主办单位: “千人计划”专家联谊会生物医药和生命科学专业委员会
中国生化与分子生物学会核糖核酸专业委员会
中国科学院广州生物医药与健康研究院
呼吸疾病国家重点实验室
中山大学

承办单位:广州市锐博生物科技有限公司

开幕主旨演讲

Craig Mello教授
美国麻省大学医学院教授
2006年诺贝尔生理学或医学奖
获得者

主旨演讲嘉宾

Troels Koch博士
丹麦Santaris制药公司首席技
术官,研发副总裁

Ekkehard Leberer教授
法国赛诺菲研发联盟管理高级总监, IMI COMPACT Consortium常务董事

Muthiah Manoharan博士
美国Alnylam制药公司高级副总裁,新药开发负责人

Brett Monia博士
美国Isis 制药公司高级副总裁
Oligonucleotide Therapeutics Society当选主席

大会拟定议程

Wed, Nov 5, 2014

Registration 13:00-18:00

Thu, Nov 06, 2014 (Day 1)

 

Chair

Mano Manoharan, PhD Senior Vice President, Alnylam Pharmaceuticals, USA

08:30-08:45

Introduction

CNAF Organizing Committee

08:45-09:30

Opening Keynote

Craig Mello, PhD Professor, University of Massachusetts Medical School, HHMI, 2006 Nobel Prize Winner, USA
Title:  RNA-guided genome defense and new frontiers in biotech and medicine

09:30-10:10

Keynote

Brett Monia, PhD Senior Vice President, Isis Pharmaceuticals, OTS President, USA
Title: Transforming drug discovery for human therapeutics with antisense technology

10:10-10:35

Plenary

Judy Lieberman, MD, PhD Professor, Program Chair, Harvard Medical School, USA
Title: Targeted gene knockdown to treat cancer

10:35-10:55

Tea Break

10:55-11:20

Plenary

Matthew Porteus, MD, PhD Professor, Stanford School of Medicine, CRISPR Therapeutics Founder, USA
Title: Genome editing using engineered nucleases

11:20-11:45

Plenary

Erwei Song, MD, PhD Professor and Vice Dean, Sun Yat-Sen Memorial Hospital, China
Title: BRMS1L suppresses breast cancer metastasis by inducing epigenetic silence of FZD10

11:45-12:00

Technology

Rick Hogrefe, PhD Founder, President and Chief Executive Officer, TriLink BioTechnologies
Title: Designing a mRNA therapeutic suitable for scale up

12:00-13:30

Lunch

13:30-13:35

Chair

Brett Monia, PhD Senior Vice President, Isis Pharmaceuticals, OTS President, USA

13:35-14:15

Keynote

Troels Koch, PhD Senior Vice President and Chief Technology Officer, Santaris / Roche, Denmark
Title: LNA antisense – concepts & status

14:15-14:40

Plenary

Dmitry Samarsky, PhD Executive Vice President, Technology Development, RiboBio, China
Title: In vivo delivery of therapeutic oligonucleotides and potential applications for cancer

14:40-15:05

Plenary

Georg Sczakiel, PhD Professor, University of Lübeck, Germany
Title: Target RNA is involved in guide strand loading of Argonaute-2 and siRNA-induced RNA interference

15:05-15:25

Tea Break

15:25-15:50

Plenary

Peixuan Guo, PhD Professor, William S. Farish Fund Endowed Chair, University of Kentucky, USA
Title: A new generation of drugs from the emerging field of RNA nanotechnology

15:50-16:15

Plenary

Yi Jin, PhD Executive Vice President, Suzhou Ribo Life Science, China
Title: RNAi based therapeutics for Hepatitis B

16:15-16:30

Technology

Suresh Srivastava, PhD Founder and President, ChemGenes, USA
Title: BMEG oligonucleotides for efficient cellular delivery for therapeutic and molecular biological applications

16:30-16:55

Plenary

David Lewis, PhD Chief Scientific Officer, Arrowhead Research Corporation, USA
Title: Using Dynamic Polyconjugate (DPC) technology to advance RNAi-based therapeutics

16:55-17:00

Day End

CNAF Organizing Committee

Fri, Nov 07, 2014 (Day 2)

09:00-09:05

Chair

Troels Koch, PhD Senior Vice President and Chief Technology Officer, Santaris / Roche, Denmark

09:05-09:45

Keynote

Ekkehard Leberer, PhD Professor, Senior Director of R&D Alliance Management, Sanofi, Germany
Title: Nucleic acid therapeutics: opportunities and challenges for innovation in drug development

09:45-10:10

Plenary

William Marshall, PhD President and Chief Executive Officer, Board Director, miRagen Therapeutics, USA
Title: Discovery and development of microRNA targeting therapeutics

10:10-10:35

Plenary

Micky Tortorella, PhD Chief Technology Officer and Vice President for Drug Discovery and Technology Transfer, Guangzhou Institutes of Biomedicine and Health, China
Title: Intra-articular delivery of siRNA-conjugates as new disease modifying osteoarthritis drugs

10:35-10:55

Tea Break

10:55-11:20

Plenary

Chengyu Jiang, PhD Professor, Chair, Peking Union Medical College, CAMS, China
Title: Hsa-miR-1246, hsa-miR-320a and hsa-miR-196b-5p inhibitors can reduce the cytotoxicity of Ebola virus glycoprotein in vitro

11:20-11:45

Plenary

Marc Lemaitre, PhD Chief Executive Officer, Sirnaomics, USA / China
Title: Improving siRNA therapeutics using polymer-nanoparticle (PNP) delivery: recent pre-clinical results with STP705 against skin scars

11:45-12:00

Technology

Kimo Sanderson Vice President, Asahi Kasei, Japan
Title: Therapeutic oligonucleotides from discovery to development: the importance of proper production and scale up

12:00-13:30

Lunch

13:30-13:35

Chair

William Marshall, PhD President, Chief Executive Officer, Board Director, miRagen Therapeutics, USA

13:35-14:15

Keynote

Mano Manoharan, PhD Senior Vice President, Alnylam Pharmaceuticals, USA
Title: Chemical strategies for systemic delivery of RNAi drugs

14:15-14:40

Plenary

Dirk Haussecker, PhD Founder and Curator, RNAi Therapeutics Blog, Germany
Title: RNA therapeutics emerging as major drug discovery engine

14:40-15:05

Plenary

TBD

15:05-15:20

Technology

Carina Andersson, PhD Marketing Head, GE, USA
Title: A manufacturing solution of oligonucleotides

15:20-15:40

Tea Break

15:40-16:05

Plenary

Sven Klussmann, PhD Chief Scientific Officer, NOXXON Pharma, Germany
Title: From bench to bedside – the conversion of mirror-image oligonucleotides into therapeutics

16:05-16:30

Plenary

Ryszard Kole, PhD Distinguished Scientist, Professor, Sarepta Therapeutics, USA
Title: Eteplirsen, a phosphorodiamidate morpholino oligonucleotide, as treatment for Duchenne muscular dystrophy (DMD)

16:30-16:55

Plenary

René Thürmer, PhD Deputy Head of the Unit Pharmaceutical Biotechnology, BfArM - Federal Institute for Drugs and Medical Devices, Germany
Title: Regulatory aspects of nucleic acids therapeutics

16:55-17:15

Closing Remarks

Craig Mello, PhD Professor, University of Massachusetts Medical School, HHMI, 2006 Nobel Prize Winner, USA

会议时间:2014年11月5-7日
会议地点:广州科学城翡翠皇冠假日酒店
会议语言:英语
论坛网站:www.cnaf.org.cn
参会注册:注册优惠将于9月30日截止!点此注册

赞助企业







联系我们:

赞助咨询:
杨先生
电 话:(020)32290221-641;18933996781
邮 箱:sponsorship@cnaf.org.cn

注册及其他咨询:
官小姐
电 话:(020)32290221-656
邮 箱:register@cnaf.org.cn ; info@cnaf.org.cn



广州核酸国际论坛会务组委托 生物通 设计制作